The Gut Microbiota and Nonalcoholic Fatty Liver Disease

Seminars in Liver Disease

Volumn 35, Issue 3, 2015, Pages 262-269

  Quigley, Eamonn M ^a   Monsour, Howard P ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

gut barrier; metabolic syndrome; microbiome; nonalcoholic fatty liver disease; probiotics; steatosis

Indexed keywords

ANTIBIOTIC AGENT; PREBIOTIC AGENT; PROBIOTIC AGENT;

ARTICLE; CONCEPTUAL FRAMEWORK; DISEASE COURSE; HOST; HUMAN; INTESTINE FLORA; INTESTINE FUNCTION; LIVER CARCINOGENESIS; METABOLIC SYNDROME X; MICROBIAL POPULATION DYNAMICS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; STEATOSIS; SYSTEMATIC REVIEW (TOPIC); ANIMAL; BLOOD; GASTROINTESTINAL TRACT; HOST PATHOGEN INTERACTION; LIVER; METABOLISM; MICROBIOLOGY; NON-ALCOHOLIC FATTY LIVER DISEASE; PROGNOSIS; RISK FACTOR;

ANIMALS; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HOST-PATHOGEN INTERACTIONS; HUMANS; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; PROBIOTICS; PROGNOSIS; RISK FACTORS;

EID: 84941918492     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0035-1562946     Document Type: Article

References (102)

1. Schnabl B., Brenner D. A. Interactions between the intestinal microbiome and liver diseases. Gastroenterology: 2014; 146 6 1513 1524
2. Abu-Shanab A., Quigley E. M. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol: 2010; 7 12 691 701
3. Fraher M. H., O'Toole P. W., Quigley E. MM. Techniques used to characterise the intestinal microbiota: a guide for the clinician. Nat Rev Gastroenterol Hepatol: 2012; 9 312 322
4. Nicholson J. K., Holmes E., Kinross J., et al. Host-gut microbiota metabolic interactions. Science: 2012; 336 6086 1262 1267
5. Cho I., Blaser M. J. The human microbiome: at the interface of health and disease. Nat Rev Genet: 2012; 13 4 260 270
6. Miyake Y., Yamamoto K. Role of gut microbiota in liver diseases. Hepatol Res: 2013; 43 2 139 146
7. Chassaing B., Etienne-Mesmin L., Gewirtz A. T. Microbiota-liver axis in hepatic disease. Hepatology: 2014; 59 1 328 339
8. Janssen A. W., Kersten S. The role of the gut microbiota in metabolic health. FASEB J: 2015; 29 3111 3123
9. Quigley E. M., Stanton C., Murphy E. F. The gut microbiota and the liver. Pathophysiological and clinical implications. J Hepatol: 2013; 58 5 1020 1027
10. Cryan J. F., Dinan T. G. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci: 2012; 13 10 701 712
11. Mayer E. A., Tillisch K., Gupta A. Gut/brain axis and the microbiota. J Clin Invest: 2015; 125 3 926 938
12. Hildebrandt M. A., Hoffmann C., Sherrill-Mix S. A., et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology: 2009; 137 5 1716 24.e1, 2
13. Moschen A. R., Wieser V., Tilg H. Dietary factors: major regulators of the gut's microbiota. Gut Liver: 2012; 6 4 411 416
14. Clarke S. F., Murphy E. F., Nilaweera K., et al. The gut microbiota and its relationship to diet and obesity: new insights. Gut Microbes: 2012; 3 3 186 202
15. Claesson M. J., Jeffery I. B., Conde S., et al. Gut microbiota composition correlates with diet and health in the elderly. Nature: 2012; 488 7410 178 184
16. Hacquard S., Garrido-Oter R., González A., et al. Microbiota and Host Nutrition across Plant and Animal Kingdoms. Cell Host Microbe: 2015; 17 5 603 616
17. Doré J., Blottière H. The influence of diet on the gut microbiota and its consequences for health. Curr Opin Biotechnol: 2015; 32 195 199
18. Yatsunenko T., Rey F. E., Manary M. J., et al. Human gut microbiome viewed across age and geography. Nature: 2012; 486 7402 222 227
19. Mutlu E. A., Gillevet P. M., Rangwala H., et al. Colonic microbiome is altered in alcoholism. Am J Physiol Gastrointest Liver Physiol: 2012; 302 9 G966 G978
20. Jernberg C., Löfmark S., Edlund C., Jansson J. K. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J: 2007; 1 1 56 66
21. Fouhy F., Guinane C. M., Hussey S., et al. High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin. Antimicrob Agents Chemother: 2012; 56 11 5811 5820
22. Cox L. M., Blaser M. J. Antibiotics in early life and obesity. Nat Rev Endocrinol: 2015; 11 3 182 190
23. Cho I., Yamanishi S., Cox L., et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature: 2012; 488 7413 621 626
24. Lobstein T., Jackson-Leach R., Moodie M. L., et al. Child and adolescent obesity: part of a bigger picture. Lancet: 2015;;(e-pub ahead of print)
25. Nobili V., Alkhouri N., Alisi A., et al. Nonalcoholic fatty liver disease: a challenge for pediatricians. JAMA Pediatr: 2015; 169 2 170 176
26. Sayin S. I., Wahlström A., Felin J., et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab: 2013; 17 2 225 235
27. Li F., Jiang C., Krausz K. W., et al. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun: 2013; 4 2384
28. Szabo G., Bala S., Petrasek J., Gattu A. Gut-liver axis and sensing microbes. Dig Dis: 2010; 28 6 737 744
29. Quigley E. MM, Marsh M. N., Shaffer J. L., Markin R. S. Hepatobiliary complications of total parenteral nutrition. Gastroenterology: 1993; 104 1 286 301
30. Terjung B., Spengler U. Atypical p-ANCA in PSC and AIH: a hint toward a leaky gut? Clin Rev Allergy Immunol: 2009; 36 1 40 51
31. Terjung B., Söhne J., Lechtenberg B., et al. p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut: 2010; 59 6 808 816
32. Quigley E. M. Gastrointestinal dysfunction in liver disease and portal hypertension. Gut-liver interactions revisited. Dig Dis Sci: 1996; 41 3 557 561
33. Thalheimer U., Triantos C. K., Samonakis D. N., Patch D., Burroughs A. K. Infection, coagulation, and variceal bleeding in cirrhosis. Gut: 2005; 54 4 556 563
34. Fukui H. Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia. World J Hepatol: 2015; 7 3 425 442
35. Teltschik Z., Wiest R., Beisner J., et al. Intestinal bacterial translocation in rats with cirrhosis is related to compromised Paneth cell antimicrobial host defense. Hepatology: 2012; 55 4 1154 1163
36. Wigg A. J., Roberts-Thomson I. C., Dymock R. B., McCarthy P. J., Grose R. H., Cummins A. G. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut: 2001; 48 2 206 211
37. Shanab A. A., Scully P., Crosbie O., et al. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8. Dig Dis Sci: 2011; 56 5 1524 1534
38. Bajaj J. S., Hylemon P. B., Ridlon J. M., et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol: 2012; 303 6 G675 G685
39. Qin N., Yang F., Li A., et al. Alterations of the human gut microbiome in liver cirrhosis. Nature: 2014; 513 7516 59 64
40. Bajaj J. S., Heuman D. M., Hylemon P. B., et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol: 2014; 60 5 940 947
41. Machado M. V., Cortez-Pinto H. Gut microbiota and nonalcoholic fatty liver disease. Ann Hepatol: 2012; 11 4 440 449
42. Ley R. E., Bäckhed F., Turnbaugh P., Lozupone C. A., Knight R. D., Gordon J. I. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A: 2005; 102 31 11070 11075
43. Turnbaugh P. J., Ley R. E., Mahowald M. A., Magrini V., Mardis E. R., Gordon J. I. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature: 2006; 444 7122 1027 1031
44. Turnbaugh P. J., Gordon J. I. The core gut microbiome, energy balance and obesity. J Physiol: 2009; 587 Pt 17 4153 4158
45. Turnbaugh P. J., Hamady M., Yatsunenko T., et al. A core gut microbiome in obese and lean twins. Nature: 2009; 457 7228 480 484
46. Murphy E. F., Cotter P. D., Healy S., et al. Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. Gut: 2010; 59 12 1635 1642
47. Parks B. W., Nam E., Org E., et al. Genetic control of obesity and gut microbiota composition in response to high-fat, high-sucrose diet in mice. Cell Metab: 2013; 17 1 141 152
48. Everard A., Belzer C., Geurts L., et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A: 2013; 110 22 9066 9071
49. Greenblum S., Turnbaugh P. J., Borenstein E. Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease. Proc Natl Acad Sci U S A: 2012; 109 2 594 599
50. de Vos W. M., Nieuwdorp M. Genomics: A gut prediction. Nature: 2013; 498 7452 48 49
51. Karlsson F. H., Tremaroli V., Nookaew I., et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature: 2013; 498 7452 99 103
52. Zupancic M. L., Cantarel B. L., Liu Z., et al. Analysis of the gut microbiota in the old order Amish and its relation to the metabolic syndrome. PLoS ONE: 2012; 7 8 e43052
53. Penas-Steinhardt A., Barcos L. S., Belforte F. S., et al. Functional characterization of TLR4 +3725 G/C polymorphism and association with protection against overweight. PLoS ONE: 2012; 7 12 e50992
54. Kim K-A, Gu W., Lee I-A, Joh E-H, Kim D-H. High fat diet-induced gut microbiota exacerbates inflammation and obesity in mice via the TLR4 signaling pathway. PLoS ONE: 2012; 7 10 e47713
55. Vijay-Kumar M., Aitken J. D., Carvalho F. A., et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science: 2010; 328 5975 228 231
56. Raman M., Ahmed I., Gillevet P. M., et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol: 2013; 11 7 868 75.e1, 3
57. Mouzaki M., Comelli E. M., Arendt B. M., et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology: 2013; 58 1 120 127
58. Zhu L., Baker S. S., Gill C., et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology: 2013; 57 2 601 609
59. Le Roy T., Llopis M., Lepage P., et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut: 2013; 62 12 1787 1794
60. Wong V. W-S, Tse C-H, Lam T. T-Y., et al. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis-a longitudinal study. PLoS ONE: 2013; 8 4 e62885
61. Jiang W., Wu N., Wang X., et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep: 2015; 5 8096
62. Dumas M. E., Barton R. H., Toye A., et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A: 2006; 103 33 12511 12516
63. Spencer M. D., Hamp T. J., Reid R. W., Fischer L. M., Zeisel S. H., Fodor A. A. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology: 2011; 140 3 976 986
64. Michail S., Lin M., Frey M. R., et al. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol Ecol: 2015; 91 2 1 9
65. Engstler A. J., Aumiller T., Degen C., et al. Insulin resistance alters hepatic ethanol metabolism: studies in mice and children with non-alcoholic fatty liver disease. Gut: 2015;; [Epub ahead of print]
66. Henao-Mejia J., Elinav E., Jin C., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature: 2012; 482 7384 179 185
67. Sawada K., Ohtake T., Hasebe T., et al. Augmented hepatic Toll-like receptors by fatty acids trigger the pro-inflammatory state of non-alcoholic fatty liver disease in mice. Hepatol Res: 2014; 44 8 920 934
68. Wagnerberger S., Spruss A., Kanuri G., et al. Toll-like receptors 1-9 are elevated in livers with fructose-induced hepatic steatosis. Br J Nutr: 2012; 107 12 1727 1738
69. Miura K., Ohnishi H. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World J Gastroenterol: 2014; 20 23 7381 7391
70. Seki E., Schnabl B. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol: 2012; 590 Pt 3 447 458
71. Jiang C., Xie C., Li F., et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest: 2015; 125 1 386 402
72. Crispe I. N. The liver as a lymphoid organ. Annu Rev Immunol: 2009; 27 147 163
73. Seo Y. S., Shah V. H. The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension. Clin Mol Hepatol: 2012; 18 4 337 346
74. Catalá M., Antón A., Portolés M. T. Characterization of the simultaneous binding of Escherichia coli endotoxin to Kupffer and endothelial liver cells by flow cytometry. Cytometry: 1999; 36 2 123 130
75. Deng M., Scott M. J., Loughran P., et al. Lipopolysaccharide clearance, bacterial clearance, and systemic inflammatory responses are regulated by cell type-specific functions of TLR4 during sepsis. J Immunol: 2013; 190 10 5152 5160
76. Hoque R., Vodovotz Y., Mehal W. Therapeutic strategies in inflammasome mediated diseases of the liver. J Hepatol: 2013; 58 5 1047 1052
77. De Minicis S., Rychlicki C., Agostinelli L., et al. Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology: 2014; 59 5 1738 1749
78. Fox J. G., Feng Y., Theve E. J., et al. Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens. Gut: 2010; 59 1 88 97
79. Yoshimoto S., Loo T. M., Atarashi K., et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature: 2013; 499 7456 97 101
80. Bindels L. B., Porporato P., Dewulf E. M., et al. Gut microbiota-derived propionate reduces cancer cell proliferation in the liver. Br J Cancer: 2012; 107 8 1337 1344
81. Barclay A. R., Beattie L. M., Weaver L. T., Wilson D. C. Systematic review: medical and nutritional interventions for the management of intestinal failure and its resultant complications in children. Aliment Pharmacol Ther: 2011; 33 2 175 184
82. Li Z., Yang S., Lin H., et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology: 2003; 37 2 343 350
83. Ma X., Hua J., Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol: 2008; 49 5 821 830
84. Velayudham A., Dolganiuc A., Ellis M., et al. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology: 2009; 49 3 989 997
85. Xu R. Y., Wan Y. P., Fang Q. Y., Lu W., Cai W. Supplementation with probiotics modifies gut flora and attenuates liver fat accumulation in rat nonalcoholic fatty liver disease model. J Clin Biochem Nutr: 2012; 50 1 72 77
86. Wagnerberger S., Spruss A., Kanuri G., et al. Lactobacillus casei Shirota protects from fructose-induced liver steatosis: a mouse model. J Nutr Biochem: 2013; 24 3 531 538
87. Okubo H., Sakoda H., Kushiyama A., et al. Lactobacillus casei strain Shirota protects against nonalcoholic steatohepatitis development in a rodent model. Am J Physiol Gastrointest Liver Physiol: 2013; 305 12 G911 G918
88. Ritze Y., Bárdos G., Claus A., et al. Lactobacillus rhamnosus GG protects against non-alcoholic fatty liver disease in mice. PLoS ONE: 2014; 9 1 e80169
89. Cani P. D., Possemiers S., Van de Wiele T., et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut: 2009; 58 8 1091 1103
90. Pachikian B. D., Essaghir A., Demoulin J. B., et al. Prebiotic approach alleviates hepatic steatosis: implication of fatty acid oxidative and cholesterol synthesis pathways. Mol Nutr Food Res: 2013; 57 2 347 359
91. Ferolla S. M., Armiliato G. N., Couto C. A., Ferrari T. C. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. World J Hepatol: 2015; 7 3 559 565
92. Lirussi F., Mastropasqua E., Orando S., Orlando R. Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev: 2007; 1 CD005165
93. Tarantino G., Finelli C. Systematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease. Future Microbiol: 2015; 10 889 902
94. Gratz S. W., Mykkanen H., El-Nezami H. S. Probiotics and gut health: a special focus on liver diseases. World J Gastroenterol: 2010; 16 4 403 410
95. Lata J., Jurankova J., Kopacova M., Vitek P. Probiotics in hepatology. World J Gastroenterol: 2011; 17 24 2890 2896
96. Paolella G., Mandato C., Pierri L., Poeta M., Di Stasi M., Vajro P. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease. World J Gastroenterol: 2014; 20 42 15518 15531
97. Buss C., Valle-Tovo C., Miozzo S., Alves de Mattos A. Probiotics and synbiotics may improve liver aminotransferases levels in non-alcoholic fatty liver disease patients. Ann Hepatol: 2014; 13 5 482 488
98. Compare D., Coccoli P., Rocco A., et al. Gut-liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis: 2012; 22 6 471 476
99. Ma Y. Y., Li L., Yu C. H., Shen Z., Chen L. H., Li Y. M. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol: 2013; 19 40 6911 6918
100. Malaguarnera M., Vacante M., Antic T., et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci: 2012; 57 2 545 553
101. Alisi A., Bedogni G., Baviera G., et al. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther: 2014; 39 11 1276 1285
102. Vrieze A., Van Nood E., Holleman F., et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology: 2012; 143 4 913 6.e7